Pd54-04 the Mark Cuban Cost Plus Drug Company Effect on Urogynecologic Drugs

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Overactive Bladder II (PD54)1 May 2024PD54-04 THE MARK CUBAN COST PLUS DRUG COMPANY EFFECT ON UROGYNECOLOGIC DRUGS Raymond Xu and Amr S. El-Haraki Raymond XuRaymond Xu and Amr S. El-HarakiAmr S. El-Haraki View All Author Informationhttps://doi.org/10.1097/01.JU.0001008724.35538.9c.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The Mark Cuban Cost Plus Drug Company (MCCPDC) is a service that makes generic drugs affordable. Cortese et al. recently published the top 9 most commonly used oral medications in treatment of Urologic conditions and showed that MCCPDC would have provided a substantial reduction in costs (∼$1.29 billion) in 2020 if they replaced the Medicare prices for the 9 generic drugs. While many of these 9 drugs are commonly used in the field of Urogynecology, they do not include antibiotics and vaginal estrogen. We sought to investigate the savings for all drugs commonly used in Urogynecology. METHODS: We reviewed all of the generic drugs provided by MCCPDC and selected those commonly used for treatment of Urogynecologic conditions (N=16). For each of the 16 drugs we identified the MCCPDC prices for the minimum 30- and maximum 90-count quantities. We then also calculated the 2021 Medicare spending for the 16 drugs. The potential savings were calculated as the difference between MCCPDC and Medicare 30- and 90-count prices, multiplied by the volume-adjusted number of units dispensed to Medicare beneficiaries in 2021. RESULTS: The total 2021 Medicare cost incurred for these 16 drugs was $860,758,140.00. The total cost of those drugs through MCCPDC calculated using the total 2021 Medicare volume was $398,382,648.47 and $241,924,289.66 for 30- and 90-count pricing, respectively. The total estimated savings was therefore $462,375,491.53 and $618,833,850.34 for 30- and 90-count pricing, respectively. CONCLUSIONS: The MCCPDC is a novel program that has tremendous implications on costs savings in the context of prescription drugs. This is particularly true for those drugs used in treatment of urogynecologic conditions that often require long-term treatment resulting in accumulated costs. While the generic drugs supplied by MCCPDC generally confer savings, not all were more cost efficient when compared to Medicare costs when using the 30-count pricing, however all drugs were more cost efficient when using the 90-count pricing. Ultimately, we believe all providers should be encouraged to use the MCCPDC service when applicable to mitigate unnecessary healthcare costs. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1144 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Raymond Xu More articles by this author Amr S. El-Haraki More articles by this author Expand All Advertisement PDF downloadLoading ...